- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent(R)2015 | First Faculty of Medicine
- Turn in hypercholesterolemia treatment - PCSK9 inhibitors. What we know about the alirocumab (product Praluent(R)) yet?2016 | First Faculty of Medicine
- Alirocumab, Praluent: Clinical studies: An overwiev2016 | First Faculty of Medicine
- LDL-cholesterol: the lower the better! We need a new lipid lowering drugs? Focus on alirokumab (Praluent)2015 | First Faculty of Medicine
- Alirocumab in patients with familial hypercholesterolemia2016 | Faculty of Medicine in Hradec Králové